Solid Tumor trials recruiting in Illinois

All Solid Tumor trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Zion
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
  NCT04300556 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago, Skokie
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago, New Lenox, Orland Park
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  NCT05245500 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• SMP-3124LP in Adults With Advanced Solid Tumors
  NCT06526819 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
  NCT06810544 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago